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Abstract 
 
Objective: To pilot-test a novel, self-use breast cancer (BC) screening decision aid (DA) 
targeting Hong Kong (HK) Chinese women at average risk of BC. 
 
Methods: Women were recruited through a population-based telephone survey using random 
digit dialing between October 2013 and January 2014. Eligible participants completed our 
baseline survey and then received the DA by post. Participants (n=90) completed follow-up 
telephone interviews one month later.  
 
Results: Most participants thought that all/most DA content was presented clearly (86.7%), 
and was useful in helping women make screening-related decisions (88.9%). It also achieved 
its expected impact of improving informed decision-making and increasing shared-
participation preference without increasing participants’ anxiety levels. Participants showed a 
modest non-statistical increase in their screening knowledge scores. Older women rated the 
perceived severity of a BC diagnosis as significantly lower, and more educated women 
reported significantly lower perceived anxiety about the disease.  
 
Conclusion: Our DA appears acceptable and feasible for self-use by HK Chinese women 
who need to make an informed decision about BC screening without increasing overall 
anxiety levels. 
 
Practice implications: This study supports the potential of self-use DAs for cancer 
screening-related decision support in a Chinese population. 
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INTRODUCTION 
Decision aids (DAs) are systematically developed interventions that support better informed 
decision making by enhancing individuals’ cognitive attributes and decision-making process 
related-outcomes, including knowledge and beliefs about a disease and its associated medical 
interventions, and improving their risk perception accuracy1. DAs play an important role in 
cancer screening with growing evidence indicating that they improve individual decision-
making process-related outcomes1-6 including reducing proportions of undecided patients and 
related decisional conflicts5,6. DAs are particularly useful when there are multiple possible 
health interventions and when each alternative has its specific benefits and harms that 
individuals might value differently7.  
 
There is a need to help women make informed choices about breast cancer (BC) screening 
based on appraisal of benefits and risks8,9, in view of unresolved debates on potential benefits 
versus harms from mammography screening in the US and Europe8,10-12. Among various 
modalities of BC detection, only mammography has been demonstrated to be effective in 
reducing disease-specific mortality11,13,14, while the effectiveness of other modalities remain 
unproven15-19. In addition to this uncertainty, false alarms, over-diagnosis and over-treatment 
have been cited as the major potential harms arising from BC screening11,19. A critical 
examination of the BC screening debate is particularly important in Chinese populations, 
especially to those living in one of the most westernized and urbanized Chinese cities, Hong 
Kong (HK), given the fact that its markedly lower BC prevalence might lead to more false 
positive cases in comparison to the Caucasian counterparts. In 2012, age-standardized 
incidence rates in the UK and US were 95 and 92.9 per 100,000 women respectively, while 
the rate in HK was 61/100,00020. Respecting screening uptake, by 2003-2004 approximately 
14.7% of women have ever attended mammography screening in Hong Kong21. More 
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recently, haphazard opportunistic mammography ultrasonography and increasingly MRI 
screening of women at average risk, have proliferated in recent years.  
 
So public information on BC screening needs appropriate balance22. Although HK does not 
provide population-based systematic BC screening, opportunistic mammography screening 
services are available in public and private hospital-based units and general outpatient clinics 
as well as in private laboratories, for a minimal user charge to potential clients. Significant 
promotion of mammography for HK Chinese women by these service providers, among 
others is seen as a means to reduce the BC-associated mortality rate21,23. However, difficulties 
in accessing scientifically validated and yet reader-friendly information on early BC detection 
practices, make it difficult for many Chinese women to weigh the pros and cons of BC 
screening before making an informed choice. Since individual judgment is a key part of any 
decision-making process, a tailored decision support tool or decision aid (DA) should help 
women formulate more realistic expectations of mammography screening and other early BC 
detection practices.  
 
Most DAs for BC screening were developed and used in Western populations7. However, 
among Chinese women at an average risk of developing BC, a culturally-relevant DA that 
informs Chinese women of available early BC detection strategies has yet to be developed 
and tested. Our previous research to develop a DA that assisted women making surgical 
treatment choices for early BC revealed that many HK Chinese women with BC preferred a 
booklet over alternative formats24. That decisional tool was also tested in a randomized 
controlled trial setting indicating benefit by reducing decisional conflicts and subsequent 
regret and enhancing clinical services in our BC population25. We have therefore developed 
and pilot-tested a print-based DA tailored for HK Chinese women that focuses on aiding 
5 
 
decision-making for early BC detection strategies. We investigated the initial acceptability 
and utility of this DA and evaluated levels and possible changes in knowledge and perceived 
risk (‘information’), and role in screening decision and decisional conflict (‘decision-process’) 
attributes in a sample of HK Chinese women. We also evaluated whether or not there was 
any systematic variation in the attributes among subgroups. 
 
METHODS 
Content development of a decision aid 
The content of the DA was developed with reference to a thorough literature review using 
PUBMED database, the latest Cochrane BC screening leaflet26, existing patient aids 
materials27, cross-reference and expert opinion. We adapted the International Patient Decision 
Aid Standards (IPDAS) framework28. Our final DA booklet was written in the traditional 
Chinese characters commonly used in HK, Taiwan and Singapore and consisted of eight 
components (Table 1). 
 
To formulate the DA content, we established a working group of neutral non-advocates to 
maintain objectivity, comprising a 7-member panel with backgrounds in statistics, 
epidemiology, public health, psycho-oncology and oncology. We reviewed common BC 
detection strategies: mammography, breast ultrasound, clinical breast examination, breast 
self-examination, and magnetic resonance imaging. These strategies are explained in the DA. 
A narrative review method was applied to the content development. Two panel members (IW, 
CNW) conducted the review using the scoping review approach29,30, which helps to identify 
appropriate ‘parameters’ (domains or scope) relating to the potential benefits, harms and 
uncertainties of BC screening practices (Details in Appendix A). The findings were then 
adapted to suit the organizational format of our DA.  
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During this stage, inconsistencies were resolved by iterative discussions in the working group 
with invited associates. Specifications regarding graphics, layout and typography design were 
passed on to a graphic design company which produced and printed the DA. Hand-drawn 
illustrations and graphical representations of proportions were used to facilitate 
comprehension. An illustrative example is shown in Appendix B. 
 
Participants and setting 
We used a prospective before-and-after survey study design to evaluate the DA effectiveness 
in helping women make informed decisions about early BC detection practices. Subjects 
were recruited by a population-based telephone survey, using random-digit dialing to obtain a 
sample from all fixed, land-based telephone lines, and within-household sampling of an 
eligible household member. If more than one female member per household met our criterion, 
she whose birthday was the closest to the date of the interview was selected. For non-
response calls, three attempts were made before number replacement. Selected respondents 
were briefed about our study and invited to participate with verbal informed consent, after 
which the baseline telephone interview commenced. We also obtained consent to mail the 
DA, and followed them up through a second telephone survey conducted a month later. 
Those who completed both baseline and the follow-up surveys were given a HK$100 
(~US$13) supermarket coupon as an incentive.  
 
Baseline telephone interviews were administered to obtain information including the 
information and decision-making process attributes and socio-demographic characteristics. 
The follow-up survey repeated the baseline telephone survey items and included additional 
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questions on the acceptability and utilization of the DA, decisional conflict and perceived 
benefits and barriers surrounding BC screening.  
 
The baseline survey (22nd October to 20th November 2013) yielded an overall response rate 
of 43.9%, while the one-month follow-up survey occurred between 22nd November 2013 and 
15th January 2014. At baseline, 126 participants consented to participate and were assessed. 
DAs were then posted to participants, three questionnaires being returned due to addressing 
errors, so 123 participants received the DA; 90/123 subsequently completed the follow-up 
interviews, giving a post-intervention response rate of 73.2%. A sample size of 90 is 
sufficient to estimate population characteristics having a mean proportion of 0.5 with an error 
margin of 0.10 and 95% confidence interval. Ethics approval was granted by the Hospital 
Authority West Cluster and HKU Institutional Review Board.  
 
Subject eligibility 
Inclusion criteria were: (1) Cantonese-speaking Chinese women aged 30 or above at average 
risk of developing BC, (2) able to give verbal consent, (3) able to read the DA, and (4) able to 
answer/respond to telephone interviews. We excluded women with a personal or significant 
family history of breast/ovarian cancer in first or second degree blood relatives because these 
women are at higher risk of BC. 
 
Outcome measures 
Outcome measures were (i) acceptability of the DA, the primary outcome measure, (ii) utility 
of the DA and other attributes, namely (iii) knowledge regarding BC screening; (iv) 
perception of personal BC risk; (v) screening decisional control preferences; (vi) decisional 
conflict and (vii) perceived benefits of and barriers to screening. DA acceptability, and utility 
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and measures (vi) to (vii) were measured during follow-up assessments, while remaining 
outcomes were measured both at baseline and follow-up assessments. 
 
Acceptability and utility 
Seven items were adapted from Smith et al’s study31. After receiving the DA, respondents 
were asked about the comprehensibility of the DA booklet relative to the amount of 
information presented, length, clarity, coverage of screening options and helpfulness for 
making BC screening decisions. We also evaluated whether the information in the booklet 
was new to the respondents. A utilization measure was used to evaluate whether the 
individuals had partially or fully read the booklet. 
 
Knowledge of BC screening 
Three simple true-false item questions focused on the potential benefits and harms for BC 
screening.  Each correct response scored 1 point. The total knowledge score was transformed 
into a rounded percentile scale for analysis.  
 
Self-perceived risk of developing BC 
Perceived risk assessment comprised five domains: (i) self-rated five-year risk of developing 
BC; (ii) comparative risk at own age (perceived personal risk of developing BC, compared to 
other women at their own age);  (iii) perceived severity of a BC diagnosis; (iv) perceived BC 
anxiety and (v) perceived worry about developing BC during their lifetime. Sub-domain 
scores (i) to (iv) ranged from 1 (“impossible”/“much lower”/“strongly disagree”) to 5 
(“certain”/“much higher”/“strongly agree”), excepting the sub-domain scores (v) for 
perceived worry, scored 1 (not at all) to 7 (all the time). 
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Preference for control in decision making process 
The validated Control Preference Scale was used32. Respondents were asked “Who should 
make screening decisions?” For analyses, responses were collapsed to reflect active decision-
making styles (a women should make her own screening decision without or after 
considering doctor’s opinion), collaborative style (decision-making shared with a doctor), and 
passive styles (doctors decide for a women after/without considering the woman’s 
preference). 
 
Decisional conflict 
Decisional conflict, measured by the validated Chinese version of Decisional Conflict Scale 
(DCS)33, reflects the aversive subjective experience of indecisiveness34, when choice (here 
choice of screening) among competing options (screening modalities) involves potential risk, 
regret or challenge to the life values of the individual concerned35. For each of 16 questions 
covering five domains (uncertainty, informed, value clarity, support and effective decision) 
five responses were possible: ‘yes’, ‘probably yes’, ‘unsure’, ‘probably no’ and ‘no’. For 
analyses, each item response was scored 0 to 4, individuals’ total scores obtained being then 
standardized into a scale from 0 (no decisional conflict) to 100 (extreme decisional conflict).  
 
Perceived benefits and barriers 
We surveyed and summarized important perceived factors (namely, benefits and barriers) 
associated with a particular health decision on BC screening practices that lead to having or 
not having regular screening for BC. Listed benefits included early detection at less advanced 
stages, understanding of health condition, and, reduced chance of dying from BC, while 
barriers included information of screening (where or how to go), screening costs, over-
diagnosis, false alarm or psychological pressure. 
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Statistical analyses 
Descriptive statistics were used to summarize subject characteristics, acceptability and utility 
of the DA. We used Wilcoxon signed rank/Kappa significance test to assess statistical 
significance of differences/concordance in our outcome measures (knowledge scores and 
decision making preference, respectively) on repeated measurements at the time of baseline 
and follow-up assessments. We applied multiple linear regression and logistic regression 
models to adjust for the potential confounding effects of age and socio-economic status 
(educational level and monthly household income). We used the conventional level of 
statistical significance of 0.05. All analyses were performed by using STATA version 13.0. 
 
RESULTS 
Subject characteristics 
Table 2 summarizes the sample characteristics at baseline and follow-up assessments. Most 
participants were aged 50 or above and born in HK. They commonly had two or more 
children, had completed at least secondary education, and were not covered by private 
medical insurance. More than 40% of participants rated their own health status as fair or poor. 
There was no statistically significant socio-demographic difference (all p-values > 0.05) 
between the baseline sample and the participants who completed both rounds of survey 
(Table 2). There was also no statistically significant differences for other attributes 
(including level of knowledge related to breast cancer screening, perception of personal 
breast cancer risk, screening decisional control preferences) between drop-outs and those 
completing both surveys (data not shown). Thus, we restricted our analyses to respondents 
completing both surveys (n=90).  
 
Acceptability and utility of the DA 
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We examined if the format of the piloted DA needed improvement by checking the responses 
to questions about preference for and satisfaction with the sections and presentation format of 
the booklet. Acceptability of the DA booklet was generally high (Table 3). Most participants 
indicated that the amount of information provided was ‘about right’ (n = 66, 73.3%) and that 
the length of the DA presentation was ‘about right’ (n = 76, 84.4%). Most participants also 
felt that DA content was generally presented clearly (86.7%), and was very/somewhat helpful 
in their BC screening decision-making (88.9%). About half of the respondents (57.8%) felt 
that coverage of different screening modalities was balanced, though some women found the 
presentation slanted towards mammography (15.6%). Most participants (53.3%) preferred 
BC information in a booklet format to a web-based form (22.2%) or mobile application 
(22.2%).  
 
In the DA booklet, the most commonly viewed components were the disease rates in HK and 
the benefits of the screening practices, with 98.9% of participants reportedly read these 
sections, whereas  the 5-point executive summary (86.7% of participants read this) and the 
section on uncertainties of screening practices (87.8% of participants read this) were the least 
commonly viewed sections (data not shown). Respondents generally rated the quality of each 
section favorably: more than half of the women rated the sections as excellent/good, and only 
a few women (1.3%) rated one of the sections (on value clarification and guidance to 
reaching decisions) as being poor (data not shown). Appendix Table C.1 lists the important 
perceived benefits and perceived barriers regarding regular screening. The strongest 
perceived benefits were: early discovery of BC at a less advanced stage (42.2%), and; 
knowing more about one’s health condition (42.2%). Conversely, the leading barriers were: 
lack of adequate information on where or how to obtain screening (14.4%), and; concern 
about the risk of getting BC (14.4%). 
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Other outcome measures 
Overall knowledge scores in pre- (61/100) and post- (63/100) assessments showed 
participants were generally knowledgeable, though significant knowledge gains over time 
were not  observed (Table 4). Using multivariable regressions, comparisons of information 
measures (pre- versus post-intervention) by socio-demographic subgroups showed no 
statistical changes in subgroup knowledge levels. Age, however, appeared to be marginally 
important (adjusted OR=1.03, 95% CI=(0.99, 1.09)) (Table 5). Furthermore, we found no 
statistically significant changes in women’s self-rated 5-year BC risk and comparative risk at 
their own ages, after adjusting for the effects of age, educational level and monthly household 
income. However, older women perceived significantly less severity from a BC diagnosis 
(β=-0.03, 95% CI=(-0.06,-0.01)), and more educated women reported significantly less 
anxiety about developing the disease during their lifetime (β=-0.85, 95% CI=(-1.47,-0.24)) 
(Table 5).  
  
Overall, at both baseline and follow-up (46.1% and 50.0%, respectively), many women 
indicated preference for an active decision-making role regarding BC screening. Notably, 
preferred involvement in screening decision-making changed significantly (p-value for kappa 
= 0.99) between pre- and post-intervention assessments. At follow-up far fewer women 
(30.0%) preferred a passive role compared to at baseline (48.3%) and, more women favored 
an active or collaborative decision-making role at follow-up (70.0%) compared to baseline 
(51.7%) (Table 4). We then investigated if any subgroup of women demonstrated significant 
changes from passive style to active or collaborative styles in their decision control 
preference after having read the DA. The results revealed that age and monthly household 
income were unrelated to changes in control preference, but a significant relationship 
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between educational level and changes in decision control preference from passive style to 
active/collaborative styles was observed (adjusted OR=0.36, 95% CI=(0.15, 0.84)) (Table 5).  
 
Finally, we investigated decisional conflict among our participants after receiving the DA. 
The mean value for the total DCS scores indicated a low degree of decisional conflict among 
our participants. The scores for uncertainty, feeling uninformed, feeling unclear about 
personal values, insufficient support and ineffective decision subscales were relatively low, 
being below 22 (standardized to a scale of 0-100) (Table 4).  
 
DISCUSSION AND CONCLUSIONS 
We developed and pilot-tested a decision aid booklet that covers aspects of early BC 
detection strategies tailored for HK Chinese women at average risk of BC. Respondents’ 
reports of acceptability and utility indicated that this DA was effective in helping readers 
understand the importance of informed decision-making, and importantly, prompted a 
preference for more active/collaborative participation styles in screening decision-making 
without elevating self-reported anxiety and worry at follow-up. This provides preliminary 
evidence that our DA could provide decisional support to Chinese women facing multiple 
screening options and help them recognize potential benefits and risks of screening choices. 
Such an aid is particularly relevant for the Chinese female population, as there is currently 
insufficiently diverse evidence available in Chinese indicating the ‘best’/‘optimal’ screening 
choice.  
 
Just over half of the women preferred the booklet format (53.3%) over website and mobile 
application (44.2%) formats, consistent with our recent study that developed a DA for women 
facing BC surgical treatment choices25. However, web-based or mobile-phone application 
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DAs may become important in the near future, as a cohort who have grown up with mobile 
technology enters the risk range for BC, altering preferred sources of health information. A 
recent systematic review concluded that internet-based DAs in general do not produce 
contradictory impacts to what is commonly found in conventional DAs7. More research is 
needed on preferences and utilities of DAs in innovative formats7, especially as internet 
popularity grows. 
 
About one-in-eight respondents did not read the section addressing potential uncertainties 
surrounding screening practices detailing the international debate about BC mortality 
reductions. Ambiguity of benefit will not generally clarify choice, but may ensure a default 
“no decision” state persists. People undecided on a topic remain equivocal when presented 
with mixed information, but those who have made a decision preferentially select information 
supporting that decision36.  Anecdotally, local media messages emphasize ‘early detection 
and prevention equals unequivocal good’ while efforts to emphasize the limitations of 
screening are far fewer, potentially biasing women’s values and preferences towards BC 
screening.  These attitudinal and socio-cultural factors can hinder an individual’s informed 
decision-making and lower her ability to make an autonomous screening choice.  Some 
women might skip the factual material due to comprehension difficulties. Some participants 
suggested the inclusion of real-life stories and contact information for hospitals and clinics 
offering screening services would improve the content. These comments suggested that 
Chinese women may make informed decisions based not only on personal benefits and risks 
but also on actions of others who have faced similar problems. Peer conformity is an 
important determinant of Chinese people’s vaccination and influenza-related hygiene 
behaviours37. This may also influence more general cancer-related decisions in Chinese 
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populations38. Providing contact information of health institutions, on the other hand, may 
help women to access screening services. 
 
Participants showed few knowledge gains regarding BC screening. Previous HK studies on 
decisions for BC surgery also failed to achieve large knowledge gains25. Among the three 
knowledge questions, most women (~92%) correctly answered was ‘If the cancer is detected 
in its early stage, the treatment that you need to undergo will be simpler’. Conversely, most 
women (~88%) also incorrectly and affirmatively answered the question ‘Regular screening 
can prevent BC’. Participants may misunderstand the function of screening. Early detection 
does simplify treatment, but screening and early detection of pre-cancerous lesions has not 
been reliably confirmed to reduce the chance of developing breast cancer10. Our findings 
suggest that most participants did not understand that the purpose of BC screening is for early 
detection of existing disease, rather than preventing the onset of BC.  
 
Significantly, there was a marked shift in participation preferences towards an active or 
collaborative role at the follow-up assessment. In other words, after having read the DA, 
more participants engaged and were demanding a greater role in making decisions regarding 
choice of BC screening. This suggests these women were empowered by the DA. Given that 
a very small increased level of self-estimated risk of contracting BC in the next 5 years and a 
lower post-intervention level of anxiety was reported, we could argue that the DA had 
heightened the respondents' awareness and improved their BC understanding without 
increasing anxiety. Moreover, since no women reported their self-rated risk of developing the 
disease to be ‘certain’ and few (n=9) rated it ‘likely’ at follow-up, the small increases in level 
of self-estimated risk appear insignificant. Incorrect perception of actual BC risk38,39 as well 
as other cancers reflects optimistic bias38. Correcting such bias would be desirable. 
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Decisional conflict which might potentially interfere with women’s decision-making 40 was 
negligible. In other words, women were unlikely to feel uncertain and uninformed about 
screening decision towards BC after reading our DA, although we cannot rule out the 
possibility that these women had low decision conflicts in general. 
 
We have demonstrated that this piloted DA for BC screening was helpful in providing 
supportive information for women during their decision-making, but the effects appeared 
much weaker among women with lower education and literacy levels, consistent with other 
studies31. Less educated women reported higher perceived anxiety about developing the 
disease during their lifetime (Table 5). Post hoc, this subgroup was found to also have poorer 
self-rated health compared to the other study participants, and therefore might be more likely 
to report  higher level of anxiety. 
  
Several limitations need to be acknowledged. First, our analyses were based on data gathered 
from a longitudinal study design, using a small sample size possibly explaining why our 
hypothesized relationships were insignificant and could have restricted the potential to 
identify differences in outcome measures in subgroups. The second limitation is the potential 
for desirability bias in responses to the questions on knowledge of BC screening. Moreover, 
we could not rule out the possibility of whether the participants might already have 
committed to a particular BC screening practice or hold established beliefs about these. This 
may have affected women’s willingness to accept information that possibly conflicted with 
their health practices or beliefs about screening. Also, we lacked data about women’s 
screening intention at both pre- and post-intervention assessments. A randomized control trial, 
therefore, would provide a ’gold-standard’ for evaluating the effectiveness of the DAs in 
changing outcomes in women’s BC screening decision-making. However, as a first step, this 
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pilot study illustrated the feasibility and the acceptability of the DA booklet, and appears to 
have boosted shared participation preference among women. Third, our study tested the 
piloted DA as a decision-support tool for self-use in non-clinical settings. This is desirable 
because it does not increase clinicians’ workloads. However, future research can explore 
applicability to consultations in primary care setting.   
 
CONCLUSIONS 
The DA's impact on fostering informed decision making for Chinese women was positive, 
decision-making participation preference was heightened and the booklet was well received 
by users. Future research on the effectiveness of the DA in prompting more informed 
screening behaviour should be assessed in a randomized controlled trial.  
 
PRACTICE IMPLICATIONS 
Most DAs for BC screening are developed for Western populations. This tailored DA on BC 
screening for Chinese women facing screening decisions improved women’s desire for 
involvement in BC screening decision-making. In Chinese contexts there is a higher 
likelihood for a screening false alarm due to the relatively low disease prevalence in the 
population. The availability of more neutral information on the possible benefits, harms and 
uncertainties associated with screening options makes for more informed decisions. Whether 
the DA prompts changes in screening practices and improves Chinese women’s ability to 
make autonomous choices in cancer-related decisions awaits confirmation.  
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Table 1 Table of contents of the booklet 
Sections Content descriptions 
(1) Is breast cancer common in Hong Kong? Provide information on incidence and mortality of 
breast cancer in Hong Kong. 
(2) What is breast cancer screening? Introduce and describe breast cancer screening 
modalities including mammography, ultrasound, 
clinical breast examination, breast self-
examination and magnetic resonance imaging. 
(3) Assess your risk and consider trade-offs Include information on structured guidance in 
reaching a decision, and provide a summary 
table to review the potential benefits and costs of 
the available modalities and options for early 
detection of breast cancer. 
(4) What are the benefits of breast cancer 
screening? 
Discuss benefits of the screening modalities, e.g., 
reduction in mortality and sensitivity. 
(5) What are the risks of breast cancer 
screening? 
Discuss risks of the screening modalities, e.g., 
over-diagnosis, false positives, and psychological 
consequences such as anxiety. 
(6) What are the uncertainties of breast cancer 
screening? 
Discuss uncertainties of the screening modalities, 
e.g., impact on reducing mortality from breast 
cancer. 
(7) Making informed decisions Explain the importance of making informed 
decisions and considerations involved. 
(8) References Scientific studies and evidence cited. 
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Table 2 Demographic characteristics of study sample before (baseline / pre-intervention) or after 
receiving the DA booklet (evaluation / post-intervention) 
Variables All participants Participants 
who have 
completed 
the 
evaluation 
survey 
p-value* 
 n = 126 (%) n = 90 (%)  
Characteristics    
Age, y   0.997 
  Mean (SD) 54.7 (13.17) 54.3 (12.42)  
  30-39 17 (13.5) 12 (13.3)  
  40-49 27 (21.4) 19 (21.1)  
  50-59 39 (31.0) 29 (32.2)  
  60-69 27 (21.4) 20 (22.2)  
  ≥70 16 (12.7) 10 (11.1)  
No. of children    
  Nil 17 (13.5) 12 (13.3) 0.985 
  1 32 (25.4) 22 (24.4)  
  2 or more 77 (61.1) 56 (62.2)  
Place of birth   0.328 
  Hong Kong 74 (58.7) 55 (61.1)  
  Mainland China (including Macau) 46 (36.5) 34 (37.8)  
  Others 6 (4.8) 1 (1.1)  
Education*    
  Primary or less 26 (20.6) 16 (17.8) 0.855 
  Secondary 73 (57.9) 55 (61.1)  
  Tertiary or more 27 (21.4) 19 (21.1)  
Family monthly income   0.953 
  <$10,000 26 (21.0) 21 (23.3)  
  $10,000 - 19,999 33 (26.6) 24 (26.7)  
  $20,000 - 29,999 17 (13.7) 13 (14.4)  
  $30,000 - 39,999 23 (18.5) 13 (14.4)  
  ≥$40,000 24 (19.4) 18 (20.0)  
  Unstable 1 (0.8) 0 (0.0)  
  Missing 2 1 (1.1)  
Status of medical insurance that covers breast 
check-up   0.683 
  Insured by oneself or family 18 (14.3) 10 (11.1)  
  Insured by employer or family members' employer 8 (6.3) 4 (4.4)  
  Not covered by any medical insurance 106 (84.1) 78 (86.7)  
Breast cancer screening   0.862 
  Have heard of 25 (19.8) 17 (18.9)  
  Have not heard of 101 (80.2) 73 (81.1)  
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Preferred format of DA   0.717 
  Booklet 58 (46.0) 48 (53.3)  
  Website 26 (20.6) 20 (22.2)  
  Mobile application 32 (25.4) 20 (22.2)  
  Don't know / Difficult to say 10 (7.9) 2 (2.2)  
Self-rated health status   0.875 
  Excellent / Very good 26 (20.6) 21 (23.3)  
  Good 48 (38.1) 32 (35.6)  
  Fair / Poor 52 (41.3) 37 (41.1)  
SD=standard deviation 
 
 
* Significance tests for evaluating whether there was any socio-demographic difference between the 
overall baseline sample and the participants that completed both rounds of survey. 
**Some percentages do not add up to 100% because of rounding error 
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Table 3 Acceptability of the decision aid booklet (n = 90) 
Measures Number % 
Acceptability   
Amount of information provided*   
  About right 66 73.3 
  Too little 14 15.6 
  Too much 5 5.6 
  Don't know / Difficult to say 5 5.6 
Length of DA*   
  About right 76 84.4 
  Too short 3 3.3 
  Too long 9 10.0 
  Don't know / Difficult to say 2 2.2 
Clarity   
  Everything is clear 27 30.0 
  Most things are clear 51 56.7 
  Some things are clear 12 13.3 
  None of the information is clear 0 0 
Balanced presentation*   
  Balanced 52 57.8 
  Slanted towards mammography 14 15.6 
  Slanted towards breast U/S 0 0 
  Slanted towards CBE 7 7.8 
  Slanted towards BSE 6 6.7 
  Slanted towards MRI 7 7.8 
  Don't know / Difficult to say 4 4.4 
Help in decision-making about 
breast cancer screening   
  Very helpful / Somewhat helpful 80 88.9 
  Little helpful / Not helpful 3 3.3 
  Neutral 7 7.8 
DA content is   
  Totally new 11 12.2 
  Mostly new 45 50.0 
  Mostly already known 27 30.0 
  Something already known very well 6 6.7 
  Don't know / Difficult to say 1 1.1 
‘Would you recommend the 
decision aid booklet to others?’   
  Definitely would 40 44.4 
  Probably would 40 44.4 
  Not sure 5 5.6 
  Probably would not 3 3.3 
  Definitely would not 2 1.1 
  Don’t know 1 1.1 
26 
 
U/S=ultra-sound, CBE=clinical breast examination, BSE=breast self-examination, MRI= magnetic 
resonance imaging 
*The scores do not add up to 100% because of rounding error 
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Table 4. Outcomes on informed decision making (IDM) of study sample before (baseline / pre-
intervention) or after receiving the DA booklet (evaluation / post-intervention) 
IDM outcomes Baseline 
assessment, 
% 
n=90 
Follow-up 
assessment, 
% 
n=90 p-value for t-test 
Knowledge level*   0.34 
  Mean (SD) 60.7 (19.7) 61.9 (19.1)  
Preference for control in IDM   p-value for 
kappa test 
  Active 46.1 50.0 0.99 a 
  Collaborative 5.6 20.0  
  Passive 48.3 30.0  
Self-perceived risk for breast cancer b Mean (SD) Mean (SD) p-value for 
signed-rank test 
  Self-rated 5y risk 1.4 (0.9) 1.9 (1.0) 0.01 
  Comparative risk at own age 2.3 (0.8) 2.4 (0.7) 0.12 
  Perceived severity of contracting the disease 2.8 (1.3) 2.9 (1.5) 0.77 
  Perceived anxiety 3.7 (1.3) 3.4 (1.5) 0.17 
  Perceived worriness 3.0 (1.6) 2.9 (1.5) 0.87 
Decision Conflict c  Mean (SD)  
  Total score  14.8 (9.7)  
  Informed subscale  21.4 (15.5)  
  Support subscale  16.0 (15.8)  
  Effective decision subscale  15.6 (15.2)  
  Value clarity subscale  11.3 (11.6)  
  Uncertainty subscale  9.4 (13.0)  
SD=standard deviation 
 
*Knowledge score ranged from 0 to 100. 
a Kappa test is testing the null hypothesis that there is no agreement between two assessments (i.e., 
pre- and post-intervention assessments in our context). Therefore, p-value>0.05 reflects that there is 
evidence of disagreement between two assessments. 
b Sub-domain scores for self-perceived risk for breast cancer range from 1 (impossible/much 
lower/strongly disagree) to 5 (certain/much higher/strongly agree), except that the scores for 
perceived worriness ranges 1 (not at all) to 7 (all the time). 
c Decision Conflict scale range from 0 to 100. The higher the score, the higher decisional conflict is. 
This also applies to other listed subscales. Specifically, uncertainty sub-score ranges from 0 (feels 
extremely certain about best choice) to 100 (feels extremely uncertain about best choice). Informed 
sub-score ranges from 0 (feels extremely informed) to 100 (feels extremely uninformed). Value clarity 
sub-score ranges from 0 (feels extremely clear about personal values for benefits and risks/side 
effects) to 100 (feels extremely unclear about personal values). Support sub-score ranges from 0 
(feels extremely supported in decision making) to 100 (feels extremely unsupported in decision 
making). Effective decision sub-score ranges from 0 (good decision) to 100 (bad decision). 
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Table 5 Effect of the decisional aid on improved level of knowledge, changes for preference for control in IDM and increase in self-perceived risk for breast 
cancer 
Variables Improved score in 
knowledge level a 
Changes in 
preference for 
control in IDM 
from passive style 
to active / 
collaborative styles 
Increase in self-perceived risk for breast cancer b 
   Self-rated 5y risk Comparative risk at 
own age 
Perceived severity 
of contracting the 
disease 
Perceived anxiety Perceived 
worriness 
 OR (95% CI) OR (95% CI) β (95% CI) β (95% CI) β (95% CI) β (95% CI) β (95% CI) 
Age 1.03 (0.99, 1.09) 1.03 (0.99, 1.08) -0.01 (-0.04, 0.02) 0.00 (-0.02, 0.01) -0.03 (-0.06, -0.01)* -0.02 (-0.06, 0.01) 0.00 (-0.02, 0.03) 
Education c 0.61 (0.26, 1.44) 0.36 (0.15, 0.84)* -0.37 (-0.93, 0.18) -0.03 (-0.31, 0.26) -0.24 (-0.75, 0.27) -0.85 (-1.47, -0.24)* 0.22 (-0.33, 0.77) 
Monthly 
household 
income d 1.13 (0.77, 1.67) 1.10 (0.77, 1.57) 0.10 (-0.16, 0.37) -0.02 (-0.15, 0.11) -0.13 (-0.36, 0.10) 0.11 (-0.17, 0.39) 0.24 (-0.01, 0.50) 
Intercept - - 1.26 (-1.10, 3.62) 0.39 (-0.87, 1.66) 2.66 (0.48, 4.83) 2.40 (-0.25, 5.05) -1.51 (-3.89, 0.88) 
IDM=informed decision making 
SD = standard deviation 
CI = confidence interval 
* p-value < 0.05 
a Improved knowledge scores (total) in the post-intervention assessment, compared to the pre-intervention assessment. 
b Sub-domain scores for self-perceived risk for breast cancer range from 1 (impossible/much lower/strongly disagree) to 5 (certain/much higher/strongly 
agree), except that the scores for perceived worriness ranges 1 (not at all) to 7 (all the time). 
c Education includes three levels: no education or primary; secondary; and tertiary or above 
d Monthly household income includes five levels: less than $10,000; $10,000-$19,999; $20,000-$29,999; $30,000-$39,999; and $40,000 or above  
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Appendix A 
Review methods 
Specifically, from January to February 2013, the PUBMED database was searched for 
retrieving research articles in English regarding these modalities' potential benefits and risks 
to women. Keywords used included 'breast cancer', 'screening', and 'decision aid'. 
International guidelines and recommendations on breast cancer screening, in addition, were 
consulted to provide a more thorough explanation of the relevant benefits and harms. Initial 
search resulted in 2,260 records. The records were then scanned by title and abstract; 
irrelevant records were discarded. Related articles and reference lists from potentially 
relevant papers were also searched and experts consulted that no important research was 
missed. At the end, 38 records were reviewed, and their findings were summarized (Table 
below). 
 
Table A.1 Summary of benefits, harms, and uncertainties of breast cancer screening 
Aspects Items Main reference(s) (First author, year of 
publication, country) 
Benefits (i) Reduction in breast cancer 
mortality 
• Public Health Agency of Canada (2010) 
Canada14 
• Kalager (2010) Norway13 
• Independent UK Panel on Breast Cancer 
Screening (2012) UK11 
(ii) Early detection of breast cancer • Public Health Agency of Canada (2010) 
Canada14 
(iii) Enhancement for awareness of 
breast diseases 
• McCready (2005) UK41 
• Dahlui (2001) Malaysia42 
Risks (i) Over-diagnosis or over-treatment • Independent UK Panel on Breast Cancer 
Screening (2012) UK11 
• The Nordic Cochrane Centre (2012) 
Denmark26 
(ii) Wrong screening results leading to 
false alarm 
• The Nordic Cochrane Centre (2012) 
Denmark26 
• Nelson (2009b) USA19 
• Chiarelli (2009) Canada43 
(iii) Anxiety, worry, and depression 
from unnecessary procedure 
• Baxter (2001) Canada18 
• Nothacker (2009) Germany44 
• Kösters (2003) Denmark45 
Uncertainties (i) Impact on reducing breast cancer 
mortality 
• Bancej (2003) Canada17 
• Teh (1998) UK15 
(ii) Differential impacts on age groups • Nelson (2009a) USA8 
• Cancer Expert Working Group on Cancer 
Prevention and Screening (2010) HK 46 
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Content development process 
The DA was first drafted by the first author (IW). The working group then critically reviewed 
and revised the content and layout of several versions of the draft DA. The ‘finalized’ booklet 
was further reviewed by female laymen readers (n = 5) who do not possess advanced 
knowledge on this topic. Revision to content and layout, where appropriate, was then made. 
Professional production editor further reviewed the content and layout of the draft booklet.  A 
guiding principle for the design of our DA was to produce a booklet that could accommodate 
the population's needs to the greatest possible extent. During the content development stage, 
inconsistencies were resolved by iterative discussions in the working group with invited 
associates. 
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Appendix B 
Example of illustration in the booklet 
The following illustration, extracted from the booklet, shows how statistics is graphically 
represented to facilitate understanding. The graphic and layout details were retouched by the 
professional graphic designers and epidemiologists. 
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Appendix Table C.1 
Appendix Table C.1 Self-reported perceived factors (i.e., benefits and barriers) that lead to regular 
screening for breast cancer and to not having it 
Factors Number Percentage 
Benefits   
To discover cancer at an early stage 38 42.2 
To know more about health condition 38 42.2 
Psychological reassurance 31 34.4 
To reduce chance of dying from breast cancer 22 24.4 
Are concerned with the risk of getting breast cancer 20 22.2 
   
Barriers   
Don’t know enough about where or how to go for screening 13 14.4 
Not concerned with the risk of getting breast cancer 13 14.4 
Costs too much 11 12.2 
Risk of over-diagnosis/over-treatment 5 5.6 
Risk of false alarm 5 5.6 
Psychological pressure, such as anxiety, worry and depression 
from follow-up procedures 
5 5.6 
Feel embarrassed 4 4.4 
 
 
